Ebenhoch Rebecca, Bauer Margit, Romig Helmut, Gottschling Dirk, Kley Jörg Thomas, Heine Niklas, Weber Alexander, Uphues Ingo, Nar Herbert, Pautsch Alexander
Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstrasse 67, 88400 Biberach an der Riss, Germany.
Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstrasse 67, 88400 Biberach an der Riss, Germany.
Acta Crystallogr D Struct Biol. 2023 Oct 1;79(Pt 10):871-880. doi: 10.1107/S2059798323006137. Epub 2023 Sep 15.
A molecular understanding of the proteins involved in fructose metabolism is essential for controlling the current spread of fructose-related obesity, diabetes and related adverse metabolic states in Western populations. Fructose catabolism starts with the phosphorylation of D-fructose to fructose 1-phosphate by ketohexokinase (KHK). KHK exists in two alternatively spliced isoforms: the hepatic and intestinal isoform KHK-C and the peripheral isoform KHK-A. Here, the structure of apo murine KHK (mKHK), which differs from structures of human KHK in overall conformation, is reported. An isoform-selective ligand, which offers a 50-fold higher potency on mKHK and human KHK-A compared with KHK-C, is further characterized. In mKHK, large-scale conformational changes are observed upon ligand binding. The structures suggest a combined strategy for the design of species- and isoform-selective KHK inhibitors.
从分子层面理解参与果糖代谢的蛋白质,对于控制当前西方人群中与果糖相关的肥胖症、糖尿病及相关不良代谢状态的蔓延至关重要。果糖分解代谢始于酮己糖激酶(KHK)将D-果糖磷酸化为1-磷酸果糖。KHK存在两种可变剪接异构体:肝脏和肠道异构体KHK-C以及外周异构体KHK-A。本文报道了脱辅基小鼠KHK(mKHK)的结构,其整体构象与人KHK的结构不同。还进一步表征了一种异构体选择性配体,该配体对mKHK和人KHK-A的效力比对KHK-C高50倍。在mKHK中,配体结合后观察到大规模构象变化。这些结构提示了一种设计物种和异构体选择性KHK抑制剂的联合策略。